SCHEMBL725078

SCHEMBL725078

COc1cc(-c2nccc3ccc(-c4ccc(F)cc4)cc23)cc(OC)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K11 Q16584 2/20 0.50
FYN P06241 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
TDO2 P48775 2/20 0.47
IDO1 P14902 1/20 0.47
GAK O14976 3/20 0.45
MAPK14 Q16539 1/20 0.44
SCN9A Q15858 1/20 0.43
TRPA1 O75762 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
BRD4 O60885 1/20 0.42
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
SLC10A2 Q12908 1/20 0.41
PAX8 Q06710 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723277 0.95 MAP3K11 (0.50) MAP3K11FYNMEN1KMT2ATDO2
SCHEMBL771403 0.91 KMT2A (0.54) MEN1KMT2AGAKCYP3A4CYP2D6
SCHEMBL724718 0.82 PDE3B (0.46) MEN1KMT2AMAPK14SCN9A
SCHEMBL21951883 0.81 KMT2A (0.53) MEN1KMT2ATDO2IDO1GAK
SCHEMBL12224207 0.80 MEN1 (0.57) MAP3K11MEN1KMT2ASCN9ABRD4
SCHEMBL28525140 0.78 SYK (0.52) MEN1KMT2AGAKCYP3A4CYP2D6
SCHEMBL17732363 0.78 MEN1 (0.43) MEN1KMT2AGAKBRD4
SCHEMBL723823 0.76 MAP3K11 (0.59) MAP3K11MEN1KMT2AGAKSCN9A
SCHEMBL723813 0.76 GAK (0.49) MAP3K11GAKBRD4
SCHEMBL804651 0.76 TUBB4A (0.47) MEN1KMT2AMAPK14PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US claimed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US claimed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US claimed
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
US-11465987-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2022-10-11 US disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
EP-3793549-A1 COMPOUNDS FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER University of Tennessee Research Foundation (US) 2021-03-24 EP disclosed
EP-3793548-A1 COMPOUNDS FOR TREATMENT OF PANCREATIC CANCER University of Tennessee Research Foundation (US) 2021-03-24 EP disclosed
CN-112512522-A Compounds for the treatment of triple negative breast and ovarian cancer 田纳西大学研究基金会 2021-03-16 CN disclosed
US-8822513-B2 Compounds for treatment of cancer GTX, INC. (US) 2014-09-02 US disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 EP disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 MAP3K11 776/4885FYN 2258/4885MEN1 165/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 MAP3K11 776/4885FYN 2258/4885MEN1 165/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 MAP3K11 776/4885FYN 2258/4885MEN1 165/4885
US-11084811-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 MAP3K11 776/4885FYN 2258/4885MEN1 165/4885
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 MAP3K11 776/4885FYN 2258/4885MEN1 165/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 MAP3K11 776/4885FYN 2258/4885MEN1 165/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 MAP3K11 776/4885FYN 2258/4885MEN1 165/4885
US-11465987-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 MAP3K11 776/4885FYN 2258/4885MEN1 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.